Stock Track | ADMA Biologics Plunges 9.82% Pre-market Following Q2 Sales Miss and After-Hours Selloff

Stock Track08-07

ADMA Biologics (NASDAQ:ADMA) is experiencing a significant pre-market plunge of 9.82% on Thursday, following a disappointing after-hours trading session on Wednesday. The sharp decline comes in the wake of the company's second-quarter financial results release, which revealed mixed performance metrics.

While ADMA Biologics met earnings expectations with $0.14 per share, representing a 7.69% year-over-year increase, the company's quarterly sales fell short of analyst estimates. ADMA reported revenue of $121.98 million, missing the consensus forecast of $122.67 million by 0.56%. Despite the miss, this figure still represents a 13.80% increase compared to the same period last year.

The market's reaction appears to be driven by the sales miss, overshadowing the company's year-over-year growth and in-line earnings. Investors seem to have expected stronger results, particularly in terms of revenue growth. The pre-market plunge follows a significant after-hours drop of over 10% on Wednesday, indicating that market participants are reassessing their expectations for the biopharmaceutical company. This movement highlights the market's sensitivity to even slight misses in revenue projections for growth-oriented companies in the biotech sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1156562616?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-07 16:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1156562616","market":"nz","top_or_hot":-1,"title":"Stock Track | ADMA Biologics Plunges 9.82% Pre-market Following Q2 Sales Miss and After-Hours Selloff","media":"Stock Track","content":"<p>ADMA Biologics (NASDAQ:ADMA) is experiencing a significant pre-market plunge of 9.82% on Thursday, following a disappointing after-hours trading session on Wednesday. The sharp decline comes in the wake of the company's second-quarter financial results release, which revealed mixed performance metrics.</p>\n\n<p>While ADMA Biologics met earnings expectations with $0.14 per share, representing a 7.69% year-over-year increase, the company's quarterly sales fell short of analyst estimates. ADMA reported revenue of $121.98 million, missing the consensus forecast of $122.67 million by 0.56%. Despite the miss, this figure still represents a 13.80% increase compared to the same period last year.</p>\n\n<p>The market's reaction appears to be driven by the sales miss, overshadowing the company's year-over-year growth and in-line earnings. Investors seem to have expected stronger results, particularly in terms of revenue growth. The pre-market plunge follows a significant after-hours drop of over 10% on Wednesday, indicating that market participants are reassessing their expectations for the biopharmaceutical company. This movement highlights the market's sensitivity to even slight misses in revenue projections for growth-oriented companies in the biotech sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ADMA Biologics Plunges 9.82% Pre-market Following Q2 Sales Miss and After-Hours Selloff</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ADMA Biologics Plunges 9.82% Pre-market Following Q2 Sales Miss and After-Hours Selloff\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-07 16:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ADMA Biologics (NASDAQ:ADMA) is experiencing a significant pre-market plunge of 9.82% on Thursday, following a disappointing after-hours trading session on Wednesday. The sharp decline comes in the wake of the company's second-quarter financial results release, which revealed mixed performance metrics.</p>\n\n<p>While ADMA Biologics met earnings expectations with $0.14 per share, representing a 7.69% year-over-year increase, the company's quarterly sales fell short of analyst estimates. ADMA reported revenue of $121.98 million, missing the consensus forecast of $122.67 million by 0.56%. Despite the miss, this figure still represents a 13.80% increase compared to the same period last year.</p>\n\n<p>The market's reaction appears to be driven by the sales miss, overshadowing the company's year-over-year growth and in-line earnings. Investors seem to have expected stronger results, particularly in terms of revenue growth. The pre-market plunge follows a significant after-hours drop of over 10% on Wednesday, indicating that market participants are reassessing their expectations for the biopharmaceutical company. This movement highlights the market's sensitivity to even slight misses in revenue projections for growth-oriented companies in the biotech sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ADMA","symbol_name":"ADMA Biologics Inc","start_time":0,"source_url":"","article_id":"1156562616","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1156562616","pubTimestamp":1754554965,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ADMA Biologics (NASDAQ:ADMA) is experiencing a significant pre-market plunge of 9.82% on Thursday, following a disappointing after-hours trading session on Wednesday. The sharp decline comes in the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ADMA":"ADMA Biologics Inc"},"translate_title":"股票追踪|ADMA Biologics盘前暴跌9.82%，因Q2销售未达预期和盘后抛售","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1},"content_text":"ADMA Biologics (NASDAQ:ADMA) is experiencing a significant pre-market plunge of 9.82% on Thursday, following a disappointing after-hours trading session on Wednesday. The sharp decline comes in the wake of the company's second-quarter financial results release, which revealed mixed performance metrics.\nWhile ADMA Biologics met earnings expectations with $0.14 per share, representing a 7.69% year-over-year increase, the company's quarterly sales fell short of analyst estimates. ADMA reported revenue of $121.98 million, missing the consensus forecast of $122.67 million by 0.56%. Despite the miss, this figure still represents a 13.80% increase compared to the same period last year.\nThe market's reaction appears to be driven by the sales miss, overshadowing the company's year-over-year growth and in-line earnings. Investors seem to have expected stronger results, particularly in terms of revenue growth. The pre-market plunge follows a significant after-hours drop of over 10% on Wednesday, indicating that market participants are reassessing their expectations for the biopharmaceutical company. This movement highlights the market's sensitivity to even slight misses in revenue projections for growth-oriented companies in the biotech sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1156562616","isCrawlerRequest":true}